Advertisement

Indian Journal of Clinical Biochemistry

, Volume 22, Issue 2, pp 60–64 | Cite as

Induction of diabetes by Streptozotocin in rats

  • A. Akbarzadeh
  • D. Norouzian
  • M. R. Mehrabi
  • Sh. Jamshidi
  • A. Farhangi
  • A. Allah Verdi
  • S. M. A. Mofidian
  • B. Lame Rad
Article

Abstract

The objective of this study is to induce experimental diabetes mellitus by Streptozotocin in normal adult Wistar rats via comparison of changes in body weight, consumption of food and water, volume of urine and levels of glucose, insulin and C-peptide in serum, between normal and diabetic rats. Intra-venous injection of 60mg/kg dose of Streptozotocin in adult wistar rats, makes pancreas swell and at last causes degeneration in Langerhans islet beta cells and induces experimental diabetes mellitus in the 2–4 days. Induction of experimental diabetes mellitus is indeed the first step in the plan of purification of pancreatic Langerhans islet cells of normal rats for transplanting under the testis subcutaneous of experimentally induced diabetic rats. Streptozotocin induces one type of diabetes which is similar to diabetes mellitus with non-ketosis hyperglycemia in some animal species. For induction of experimental diabetes in male adult rats weighted 250–300 grams (75–90 days), 60mg/kg of Streptozotocin was injected intravenously. Three days after degeneration of beta cells, diabetes was induced in all animals. The diabetic and normal animals were kept in the metabolic cages separately and their body weight, consumption of food and water, urine volume, the levels of serum glucose, insulin and C-peptide quantities in all animals were measured and then these quantities were compared. For a microscopic study of degeneration of Langerhans islet beta cells of diabetic rats, sampling from pancreas tissue of diabetic and normal rats, staining and comparison between them, were done. Induction of diabetes with Streptozotocin decreases Nicotinamide-adenine dinucleotide (NAD) in pancreas islet beta cells and causes histopathological effects in beta cells which probably intermediates induction of diabetes. In this study, we used Streptozotocin for our experiments in induction of experimental diabetes mellitus. After Induction of diabetes, consumption of food and water, volume of urine and glucose increased in the diabetic animals in comparison with normal animals, but the weight of body and the volume of insulin and C-peptide decreased in the diabetic animals. Sampling and staining of pancreas tissue of diabetic and normal rats showed that the Langerhans islet beta cells of diabetic rats have been clearly degenerated. In three days, Streptozotocin makes pancreas swell and at last causes degeneration in Langerhans islet beta cells and induces experimental diabetes. It also changes normal metabolism in diabetic rats in comparison with normal rats. Consumption of water and food, volume of urine, serum glucose increases in diabetic animals in comparison with normal rats but the levels of serum insulin, C-peptide and body weight decreases.

Key words

Diabetes Induction Streptozotocin Islet cells 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    World Health Organization: htt:/www.who.int/medacenter/factsheets/fs/138/en/Page 1–3.Google Scholar
  2. 2.
    Ikebukuro K, Adachi Y, Yamada Y, Fujimoto S, Seino Y, Oyaizu H. Treatment of Streptozotocin-induced diabetes mellitus by transplantation of islet cells Plus bone Marrow cells via portal vein in rats. Transplantation 2002; 73 (4): 512–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Rastellini C, Shapiro R, Corry R, Fung JJ, Starzl TE, Rao AS. An attempt to reverse diabetes by delayed islet cell transplantation in Humans, Transplantation proceedings 1997; 29: 2238–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Elias D, Prigozin H, Polak N, Rapoport M, Lohse AW, Cohen IR. Autoimmune diabetes induced by the b—Cell toxin STZ. Diabetes 1994; 43: 992–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Weiss RB. Streptozocin: A review of its pharmacology, efficacy and toxicity. Cancer Treatment Report 1982; 66 (3): 427–38.Google Scholar
  6. 6.
    Karunanayake EH, Hearse DJ, Mellows G. The metabolic fate and elimination of streptozocin. Biochemical Society Transactions 1975; 3: 410–14.PubMedGoogle Scholar
  7. 7.
    Bhuyan BK, Kuentzel SL, Gray LG, Wallach D, Neil GL. Tissue distribution of streptozotocin (NSC 85998). Cancer Chemotherapy Report 1974; 58: 157–65.Google Scholar
  8. 8.
    Levi JA, Wiernik PH, Diggs CH. Combination chemotherapy of advanced Previously Treated Hodgkin's disease with streptozocin, CCNU, Adriamycin and bleomycin. Medical and pediatric oncology 1977; 3: 33–40.PubMedCrossRefGoogle Scholar
  9. 9.
    Thulesen J, Qrskov C, Holst JJ, Poulsen SS. Short Term Insulin Treatment Prevents the diabetogenic action of streptozotocin in rats. Endocrinology 1997; 138 (1): 62–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Holemans K, Bree RV, Verhaeghe J, Meurrens K, Assche AV. Maternal Semi starvation and Streptozotocin-Diabetes in Rats have different effects on the in Vivo glucose uptake by peripheral tissues in their female adult offspring. The Journal of Nutrition 1997; 127: 1371–6.PubMedGoogle Scholar
  11. 31.
    Diabetes mellitus-wikipedia, the free encyclopedia, http://encyclopedia.onlinereference.info/index.php Diabetes#StatisticsGoogle Scholar

Copyright information

© Association of Clinical BIochemists of India 2007

Authors and Affiliations

  • A. Akbarzadeh
    • 3
  • D. Norouzian
    • 3
  • M. R. Mehrabi
    • 3
  • Sh. Jamshidi
    • 3
  • A. Farhangi
    • 3
  • A. Allah Verdi
    • 3
  • S. M. A. Mofidian
    • 1
  • B. Lame Rad
    • 2
  1. 1.Biometric ResearcherS.P. I. InstituteKarajIran
  2. 2.Biochemistry department of Alzahra UniversityTehranIran
  3. 3.Department of Pilot Biotechnology of Pasteur Institute of IranTehranIran

Personalised recommendations